A phase II study of systemic chemotherapy with Docetaxel, CDDP, and S-1 followed by surgery in advanced gastric cancer with extensive lymph node metastasis(JCOG1002, BulkyGC Pre-DCS Phase II)

Phase 2

• Conditions: gastric neoplasm

• Registration Number: JPRN-UMIN000006069
• Lead Sponsor: Japan Clinical Oncology Group (JCOG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-07-29
• Study Completion: 2019-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

"1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal cancer. 2) Women during pregnancy or breast-feeding. 3) Severe mental disease. 4) Under treatment with systemic steroid. 5) HBs antigen positive. 6) Under treatment with flucytosine, phenytoin, or warfarin. 7) Allergy to iodine. 8) History of hypersensitivity to DOC, CDDP, or polysorbate 80. 9) Peripheral motor neuropathy or peripheral sensory neuropathy by any reason. 10) Edema of limbs and trunk by any reason. 11) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema. 12) Active bacterial or fungal infection. 13) Past history of myocardial infarction or unstable angina pectoris within 6 months. 14) Uncontrollable hypertension. 15) Uncontrollable diabetes mellitus or routine administration of insulin."

Study & Design

• Study Type: Interventional
• Study Design: Not specified